Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
2022年8月17日 - 7:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced the
pricing of an upsized underwritten public offering with gross
proceeds of approximately $270 million. Viridian is selling a total
of 9,627,640 shares of common stock at a public offering price of
$23.50 per share and 28,084 shares of series B preferred stock at a
public offering price of $1,566.745 per share, which are
convertible into approximately 1,872,360 shares of common stock,
subject to beneficial ownership conversion limits. In addition,
Viridian has granted the underwriters a 30-day option to purchase
an additional 1,725,000 shares of common stock at the public
offering price, less underwriting discounts and commissions.
All of the shares to be sold in the underwritten
public offering are being offered by Viridian. The offering is
expected to close on or about August 19, 2022, subject to customary
closing conditions.
Viridian intends to use the proceeds from the
underwritten public offering of its shares of common stock and
series B preferred stock to further its clinical development
programs, as well as for working capital and general corporate
purposes.
Jefferies, SVB Securities and Evercore ISI are
acting as joint book-running managers for the offering. LifeSci
Capital is acting as lead manager for the offering.
A registration statement relating to these
securities has been filed with the Securities and Exchange
Commission (SEC) and became effective on November 17, 2021. A final
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC. The securities described above
have not been qualified under any state blue sky laws. This press
release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction. The offering can be made only by means
of a prospectus, copies of which may be obtained at the SEC’s
website at www.sec.gov, or by request to Jefferies LLC (Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, New
York, New York 10022; telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com), SVB Securities LLC
(Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109; telephone: 800-808-7525, ext. 6105; email:
syndicate@svbsecurities.com), or Evercore Group L.L.C. (Attention:
Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York,
New York 10055; telephone: 888-474-0200; email:
ecm.prospectus@evercore.com).
About Viridian Therapeutics,
Inc.
Viridian Therapeutics is a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies. Viridian’s most advanced
program, VRDN-001, is a differentiated monoclonal antibody
targeting insulin-like growth factor-1 receptor (IGF-1R), a
clinically and commercially validated target for the treatment of
thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R
antibody and incorporates half-life extension technology. VRDN-003
is an extended half-life version of VRDN-001. Both VRDN-002 and
VRDN-003 are designed for administration as convenient, low-volume,
subcutaneous injections. TED is a debilitating autoimmune disease
that causes inflammation and fibrosis within the orbit of the eye
which can cause double vision, pain, and potential blindness.
Viridian is based in Waltham, Massachusetts.
Note Regarding Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by the use
of words such as, but not limited to, “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” or “would” or other similar terms or expressions
that concern the company’s expectations, plans and intentions.
Forward-looking statements include, without limitation, statements
regarding the underwritten public offering and the company’s
expectations with respect to the use of the net proceeds from the
underwritten public offering. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based on the company’s current beliefs,
expectations and assumptions. New risks and uncertainties may
emerge from time to time, and it is not possible to predict all
risks and uncertainties. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements. Such forward-looking statements are
subject to a number of material risks and uncertainties including
but not limited to: the satisfaction of customary closing
conditions related to the underwritten public offering; and other
risks and uncertainties identified in the company’s filings with
the SEC, including those risks set forth under the caption “Risk
Factors” in the company’s Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission (SEC) on August 15, 2022 and
other subsequent disclosure documents filed with the SEC. Any
forward-looking statement speaks only as of the date on which it
was made. Neither the company, nor its affiliates, advisors or
representatives, undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law.
These forward-looking statements should not be relied upon as
representing the company’s views as of any date subsequent to the
date hereof.
Investor & Media Contact:
John JordanViridian TherapeuticsVice President, Investor
Relations and Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024